Search results for " transitional cell"

showing 10 items of 58 documents

Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph nod…

2009

OBJECTIVE To investigate the associations between different overall or topographically restricted lymph node (LN) variables and cancer-specific survival (CSS) after radical cystectomy (RC) and extended LN dissection (LND) with curative intent in patients with LN-positive bladder cancer. PATIENTS AND METHODS Between 2001 and 2006, 152 patients had RC with standardized extended LND for bladder cancer with curative intent. Patients with positive LNs were stratified according to the median of the LN variables (LNs removed, number of positive LNs, LN density). CSS was related to overall and topographically restricted LN variables, e.g. different levels of LND, and relationships were tested by un…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyCystectomymedicineCarcinomaHumansLymph nodeAgedAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryHazard ratioCancerMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic MetastasisLymph Node ExcisionFemaleLymphadenectomyEpidemiologic MethodsbusinessBJU International
researchProduct

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic im…

1996

To analyze the effectiveness of adjuvant polychemotherapy after radical cystectomy for non-organ-confined transitional cell bladder cancer (Stages pT3b, pT4a, and/or pN1 or pN2).Of 166 consecutive patients undergoing cystectomy at two institutions from 1987 to 1993, 80 received adjuvant polychemotherapy with methotrexate, vinblastine, and cisplatin plus doxorubicin (MVAC) or epirubicin (MVEC), whereas 86 had cystectomy only. The patients were evaluated for relapse-free survival and length of progression-free interval on the basis of follow-up data obtained in 1995 and 1996.Kaplan-Meier analysis revealed a significantly higher progression-free rate for patients after adjuvant chemotherapy (P…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansProspective StudiesProspective cohort studyLymph nodeAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemalebusinessAdjuvantFollow-Up StudiesUrology
researchProduct

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study…

1995

A total of 83 patients with nonorgan-confined bladder cancer with or without lymph node metastases (tumor stages pT3b, pT4a and/or pN1, pN2) was evaluated in November 1993 for relapse-free and overall survival. All patients underwent radical cystectomy between 1987 and 1991, 38 underwent adjuvant polychemotherapy with methotrexate, vinblastine and cisplatin plus doxorubicin (M-VAC) or epirubicin (M-VEC). Of the 83 patients 49 had entered a prospective randomized trial comparing adjuvant to no adjuvant treatment. The protocol was activated in May 1987. Patient recruitment was concluded in December 1990 because an interim analysis of the 49 randomized patients revealed a significant prognosti…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastinelaw.inventionCystectomyRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedEpirubicinCarcinoma Transitional CellUrinary bladderBladder cancerbusiness.industryMiddle AgedInterim analysismedicine.diseaseCombined Modality TherapyVinblastineSurgerySurvival Ratemedicine.anatomical_structureMethotrexateUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinbusinessmedicine.drugEpirubicinThe Journal of urology
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct

Intravesical mitoxantrone in superficial bladder tumours (Ta-T1)

1993

Abstract 36 patients with histologically proven grade G1–G2, Ta-T1 transitional cell carcinoma of the bladder were introduced, after transurethral resection (TUR), into a study of intravesical chemoprophylaxis with mitoxantrone (20 mg diluted in 50 ml). After a mean follow-up of 23 months, 16 (50%) patients showed a superficial recurrence with a mean recurrence rate of 0.56 per year. In 19 patients with recurring tumours the mean recurrence rate decreased from 1.65 to 0.58 per year. 9 patients (25.7%) suffered from a chemical cystitis that in 2 cases (5.7%) required treatment interruption.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyResectionCystitismedicineHumansCarcinoma Transitional CellMitoxantroneChemotherapyUrinary bladderbusiness.industrymedicine.diseaseSurgeryChemical cystitisAdministration IntravesicalTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyTreatment interruptionChemoprophylaxisMitoxantroneNeoplasm Recurrence Localbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma

2022

Introduction: The world population is ageing and surgical procedures for older patients are associated with higher perioperative morbidity and mortality rates than in younger patients. Segmental ureterectomy (SU) has been proposed as an alternative to radical nephroureterectomy (RNU) for selected upper tract urothelial carcinomas (UTUC), to reduce post-operative morbidity, and preserve renal function. The aim of this study was to compare RNU and SU in terms of post-operative complications, functional outcomes, and overall survival (OS) in older patients treated for UTUC. Materials and methods: Data of patients aged 75 years or older and treated for UTUC were included. The primary outcome wa…

Carcinoma Transitional CellSurvivalUreteral NeoplasmsUrologyAged; Kidney sparing surgery; Postoperative complications; Renal function; Survival; Glomerular Filtration Rate; Humans; Nephrectomy; Nephroureterectomy; Postoperative Complications; Retrospective Studies; Carcinoma Transitional Cell; Ureter; Ureteral Neoplasms; Urinary Bladder NeoplasmsCarcinomaUreteral NeoplasmNephrectomyNephroureterectomyPostoperative complicationPostoperative complicationsOncologyUrinary Bladder NeoplasmsRetrospective StudieHumansTransitional CellUreterAged; Kidney sparing surgery; Postoperative complications; Renal function; SurvivalKidney sparing surgeryRetrospective StudiesAgedRenal functionGlomerular Filtration RateHuman
researchProduct

Time to safely omit bladder cuff removal for low-risk upper tract urothelial carcinoma

2021

Carcinoma Transitional Cellmedicine.medical_specialtyUreteral Neoplasmsbusiness.industryUrologyUrologyNephrectomyText miningUrinary Bladder NeoplasmsUpper tractNephrologyCuffHumansMedicinebusinessUrothelial carcinomaMinerva Urology and Nephrology
researchProduct

Prognostic Significance of Histopathological Grading and Immunoreactivity for p53 and p21/WAF1 in Grade 2 pTa Transitional Cell Carcinoma of …

2001

At present, there are no predictors of tumour behaviour for grade (G) 2 pTa transitional cell carcinomas (TCC) of the bladder. Here we analyse the prognostic relevance of histopathological grading and the immunohistochemical detection of p53 and p21/WAF1.70 patients were newly diagnosed with G2 pTa TCC of the bladder based on transurethral resection specimens. Two pathologists, blinded with respect to the clinical outcome, confirmed the initial grade and subclassified the G2 lesions into G2a and G2b carcinomas based on the degree of nuclear atypia and the number of mitoses. Immunoreactivity for p53 and p21/WAF1 was evaluated semiquantitatively.There were 52 G2a and 18 G2b tumours, mean foll…

Cyclin-Dependent Kinase Inhibitor p21Pathologymedicine.medical_specialtyUrologyHistopathological gradingurologic and male genital diseasesCyclinsotorhinolaryngologic diseasesHumansMedicineGrading (tumors)Neoplasm StagingCarcinoma Transitional CellUrinary bladderbusiness.industryPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsP21 waf1medicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTransitional CellImmunohistochemistryNeoplasm stagingTumor Suppressor Protein p53businessEuropean Urology
researchProduct

Prognostic Value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 Immunoreactivity in pT1 G3 Urothelial Bladder Carcinomas

2001

pT1 G3 bladder carcinomas are heterogeneous with respect to tumor recurrence and progression. Whereas some urologists treat these carcinomas by repeated transurethral resections often followed by intravesical chemotherapy or BCG instillation, others recommend cystectomy after tumor recurrence or early cystectomy after the initial diagnosis. Our goal was to determine the prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in these tumors. There were 30 patients with a new histopathological diagnosis of pT1 G3 urothelial carcinoma based on a transurethral resection specimen. Representative sections of these specimens were examined for the above markers. All patients…

Cyclin-Dependent Kinase Inhibitor p21medicine.medical_specialtyPathologyTime FactorsTumor suppressor genemedicine.medical_treatmentBcl 2 baxUrologyDisease-Free SurvivalCystectomyPredictive Value of TestsCyclinsProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasm InvasivenessRetrospective Studiesbcl-2-Associated X ProteinCarcinoma Transitional CellUrinary bladderBladder cancerbiologyMembrane ProteinsGeneral MedicinePrognosismedicine.diseaseImmunohistochemistrySurvival RateKi-67 Antigenbcl-2 Homologous Antagonist-Killer Proteinmedicine.anatomical_structureTransitional cell carcinomaProto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsTumor progressionKi-67biology.proteinTumor Suppressor Protein p53Follow-Up StudiesTumor Biology
researchProduct

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

2021

Item does not contain fulltext Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors th…

Detrusor musclemedicine.medical_specialty030232 urology & nephrologyUrologyDiseaseLogistic regression03 medical and health sciencesTumor Status0302 clinical medicineRe-transurethral resection of the bladderRecurrenceRisk FactorsUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]MedicineHumansStage (cooking)Non-muscle invasive bladder cancer; Re-transurethral resection of the bladder; Residual disease; Recurrence; ProgressionNeoplasm StagingRetrospective StudiesUnivariate analysisCarcinoma Transitional CellProgressionbusiness.industryRetrospective cohort studyGeneral MedicineResidual diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Settore MED/24medicine.anatomical_structureUrinary Bladder NeoplasmsConcomitantNon-muscle invasive bladder cancerbusiness
researchProduct